Optimistic Buy Rating for Opko Health Driven by Strategic Developments and Future Prospects

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health (OPK – Research Report), retaining the price target of $3.00.

Yi Chen’s rating is based on several strategic developments and future prospects for Opko Health. Despite mixed financial results in the first quarter of 2025, with a decline in total revenue and a net loss that was less than anticipated, Chen sees potential in the company’s future revenue guidance. Management’s expectation of total revenue in the range of $675-685 million for the full year 2025, along with strategic acquisitions, supports this optimistic outlook.
Additionally, the pending transaction with Labcorp, which is expected to close in the third quarter of 2025, could streamline BioReference’s operations and enhance profitability. Furthermore, the advancement of an innovative oral dual agonist GLP-1/glucagon peptide, with plans to file an IND application later in the year, positions Opko Health at the forefront of developing treatments for obesity and metabolic disorders. These factors collectively contribute to Yi Chen’s Buy rating for Opko Health’s stock.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.